Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Scripps News on MSN7d
FDA approves standalone nasal spray to treat depressionA one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication ...
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as ... symptoms as early as 24 hours and at 28 days – without ...
The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions ... in their symptoms as early as 24 hours without the need for daily oral ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback